Study Demonstrates Clinical Validity of OncoHost’s NSCLC Test
The test guides first-line treatment selection by identifying individuals with the highest likelihood of benefit from PD-1/PD-L1 inhibitors
Read MorePosted by Andy Lundin | Mar 21, 2024 | Lung Cancer |
The test guides first-line treatment selection by identifying individuals with the highest likelihood of benefit from PD-1/PD-L1 inhibitors
Read MorePosted by Andy Lundin | Feb 22, 2024 | Diagnostic Technologies |
A research project supported by the National Institutes of Health has developed a tool to rapidly and inexpensively diagnose sarcoidosis.
Read MorePosted by Andy Lundin | Feb 16, 2024 | Cancer |
By analyzing fragments of cfDNA in a simple blood draw, the Galleri test can screen for many deadly cancers.
Read MorePosted by Andy Lundin | Jan 29, 2024 | Unknown Origin & Other Cancer Types |
New research is guiding the development of blood tests to detect and monitor responses to therapies in neuroendocrine carcinomas patients.
Read MorePosted by Andy Lundin | Jan 25, 2024 | Digital Pathology |
New research has led to the U.K. government approving the use of digital pathology to help speed up the analysis of cancer screening samples.
Read More